Our website is made possible by displaying online advertisements to our visitors.
Please consider supporting us by disabling your ad blocker.

Responsive image

Eltrombopag

Eltrombopag
Clinical data
Trade namesPromacta, Revolade, others
Other namesSB-497115-GR
AHFS/Drugs.comMonograph
MedlinePlusa609011
License data
Pregnancy
category
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability~52%[3]
Protein binding>99%
Metabolismextensive liver (through CYP1A2 and CYP2C8)
Elimination half-life21–35 hours
Excretionfeces (59%), urine (31%)
Identifiers
  • 3'-{(2Z)-2-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene]hydrazino}-2'-hydroxy-3-biphenylcarboxylic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.128.125 Edit this at Wikidata
Chemical and physical data
FormulaC25H22N4O4
Molar mass442.475 g·mol−1
3D model (JSmol)
  • CC1=NN(c2ccc(C)c(C)c2)C(=O)/C1=N\Nc1cccc(-c2cccc(C(=O)O)c2)c1O
  • InChI=1S/C25H22N4O4/c1-14-10-11-19(12-15(14)2)29-24(31)22(16(3)28-29)27-26-21-9-5-8-20(23(21)30)17-6-4-7-18(13-17)25(32)33/h4-13,26,30H,1-3H3,(H,32,33)/b27-22- checkY
  • Key:XDXWLKQMMKQXPV-QYQHSDTDSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Eltrombopag, sold under the brand name Promacta among others, is a medication used to treat thrombocytopenia (abnormally low platelet counts) and severe aplastic anemia.[3][4] Eltrombopag is sold under the brand name Revolade outside the US and is marketed by Novartis.[6] It is a thrombopoietin receptor agonist.[3] It is taken by mouth.[3][4]

Eltrombopag was discovered as a result of research collaboration between GlaxoSmithKline and Ligand Pharmaceuticals and is transferred to Novartis Pharmaceuticals.[6][7][8]

  1. ^ a b "Revolade Product Information". Therapeutic Goods Administration (TGA). Archived from the original on 23 May 2021. Retrieved 23 May 2021.
  2. ^ "Revolade 25 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 17 August 2020. Archived from the original on 23 May 2021. Retrieved 22 May 2021.
  3. ^ a b c d e "Promacta- eltrombopag olamine tablet, film coated Promacta- eltrombopag olamine powder, for suspension". DailyMed. Archived from the original on 23 May 2021. Retrieved 22 May 2021.
  4. ^ a b c "Revolade EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 23 May 2021. Retrieved 22 May 2021.
  5. ^ "Revolade Product information". Union Register of medicinal products. 15 March 2010. Retrieved 17 December 2024.
  6. ^ a b "Ligand Sells Promacta Assets and Royalty for $827 Million" (Press release). Ligand Pharmaceuticals. 5 March 2019. Archived from the original on 24 June 2021. Retrieved 17 June 2021 – via Business Wire.
  7. ^ "Revolade". GSK Canada. Archived from the original on 28 June 2021. Retrieved 17 June 2021.
  8. ^ "Novartis announces completion of transactions with GSK". Sandoz (Press release). Archived from the original on 24 June 2021. Retrieved 17 June 2021.

Previous Page Next Page






إلترومبوباغ Arabic Eltrombopag German Eltrombopag Spanish الترومبوپگ FA Eltrombopag French エルトロンボパグ Japanese 엘트롬보팍 Korean Eltrombopag Polish Eltrombopag Romanian Eltrombopag SH

Responsive image

Responsive image